专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL274651A Glucocorticoid receptor agonist and immunoconjugates thereof 未知
公开(公告)号：IL274651A
公开(公告)日：2021-04-29
申请号：IL27465120
申请日：2020-05-13
申请人： ABBVIE INC , MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , GOESS CHRISTIAN , HERNANDEZ AXEL JR , SANTORA LING C , WANG LU
发明人： MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , GOESS CHRISTIAN , HERNANDEZ AXEL JR , SANTORA LING C , WANG LU
IPC分类号： A61K38/19 , A61K47/68 , A61P1/00 , A61P17/06 , A61P19/02 , A61P29/00 , C07K16/24
摘要： Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.

2. 发明专利

IL274651D0 Glucocorticoid receptor agonist and immunoconjugates thereof 未知
公开(公告)号：IL274651D0
公开(公告)日：2020-06-30
申请号：IL27465120
申请日：2020-05-13
申请人： ABBVIE INC , MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , GOESS CHRISTIAN , HERNANDEZ AXEL JR , SANTORA LING C , WANG LU
发明人： MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , GOESS CHRISTIAN , HERNANDEZ AXEL JR , SANTORA LING C , WANG LU
IPC分类号： A61K38/19 , A61K47/68 , A61P1/00 , A61P19/02 , C07K16/24
摘要： Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.

3. 发明专利

IL274650D0 Anti-cd40 antibody drug conjugates 未知
公开(公告)号：IL274650D0
公开(公告)日：2020-06-30
申请号：IL27465020
申请日：2020-05-13
申请人： ABBVIE INC , MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , OH JASON Z , BRYANT SHAUGHN H , HERNANDEZ AXEL JR , IHLE CLAIRE L , PERNG OLIVIA A , SANTORA LING C , WANG LU
发明人： MCPHERSON MICHAEL J , HOBSON ADRIAN D , MARVIN CHRISTOPHER C , WAEGELL WENDY , OH JASON Z , BRYANT SHAUGHN H , HERNANDEZ AXEL JR , IHLE CLAIRE L , PERNG OLIVIA A , SANTORA LING C , WANG LU
IPC分类号： A61K47/68 , A61P35/00 , C07K16/28
摘要： Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.

4. 发明申请

WO2009011850A2 NOVEL THERAPEUTIC COMPOUNDS 审中-公开
标题翻译：新型治疗化合物
公开(公告)号：WO2009011850A2
公开(公告)日：2009-01-22
申请号：PCT/US2008008645
申请日：2008-07-15
申请人： ABBOTT LAB , BREINLINGER ERIC C , CUSACK KEVIN P , HOBSON ADRIAN D , LI BIN , GORDON THOMAS D , STOFFEL ROBERT H , WALLACE GRIER A , GRONSGAARD PINTIPA , WANG LU
发明人： BREINLINGER ERIC C , CUSACK KEVIN P , HOBSON ADRIAN D , LI BIN , GORDON THOMAS D , STOFFEL ROBERT H , WALLACE GRIER A , GRONSGAARD PINTIPA , WANG LU
IPC分类号： C07D249/10 , A61K31/415 , A61K31/4196 , A61K31/42 , A61P35/00 , C07D231/14 , C07D261/14 , C07D403/12
CPC分类号： C07D249/10 , C07D231/14 , C07D249/06 , C07D261/14 , C07D261/18 , C07D273/02 , C07D333/36 , C07D333/38 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.
摘要翻译：本文公开了式（I）的新化合物，其中变量如本文所定义。式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些病症和疾病，特别是炎性疾病和疾病以及增殖性疾病如癌症。

5. 发明专利

JP2014074057A 5-heteroaryl substituted indazoles as kinase inhibitors 审中-公开
标题翻译：作为激酶抑制剂的5-HETEROARYL取代的吲哚美辛
公开(公告)号：JP2014074057A
公开(公告)日：2014-04-24
申请号：JP2013266989
申请日：2013-12-25
申请人： Abbvie Inc , アッヴィ・インコーポレイテッド , Abbott Gmbh & Co Kg , アボットゲーエムベーハーウントカンパニーカーゲー
发明人： IRINI AKRITOPOULOU-ZANZE , WAKEFIELD BRIAN D , MACK HELMUT , SEAN C TURNER , ALAN F GASIECKI , GRACIAS VIJAYA J , SARRIS KATHY , KALVIN DOUGLAS M , MICHMERHUIZEN MELISSA J , SHUAI QI , PATEL JYOTI R , BAKKER MARGARETHA , NICOLE TEUSCH , ERIC F JOHNSON , KOVAR PETER J , STEVAN W DJURIC , ANDREW J LONG , ANIL VASUDEVAN , ADRIAN HOBSON , NIGEL ST JOHN MOORE , WANG LU , DAWN GEORGE , LI BIQIN , KRISTINE FRANK
IPC分类号： C07D401/04 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/429 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61P3/04 , A61P3/10 , A61P5/00 , A61P9/10 , A61P11/00 , A61P15/00 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/08 , C07D471/04 , C07D487/04 , C07D513/04
CPC分类号： C07D403/04 , C07D413/04 , C07D417/04
摘要： PROBLEM TO BE SOLVED: To provide compounds which inhibit specific combinations of kinases or target kinase pathways.SOLUTION: The present invention relates to 5-substituted indazole compounds represented by the specified general formula (I) or pharmaceutically acceptable salts of the compounds. The present invention relates also to methods of making the compounds, and to compositions containing the compounds useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim1 and nek2.
摘要翻译：要解决的问题：提供抑制激酶或靶激酶途径的特异性组合的化合物。解决方案：本发明涉及由指定的通式（I）表示的5-取代的吲唑化合物或化合物的药学上可接受的盐。本发明还涉及制备该化合物的方法，以及含有可用于抑制激酶例如糖原合酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），AKT，PAK4， PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。

6. 发明专利

JP2015007094A 新規な三環式化合物有权
标题翻译：新型三聚体化合物
公开(公告)号：JP2015007094A
公开(公告)日：2015-01-15
申请号：JP2014171336
申请日：2014-08-26
申请人：アッヴィ・インコーポレイテッド , Abbvie Inc
发明人： NEIL WISHART , MARIA A ARGIRIRADI , DAVID J CALDERWOOD , ERICSSON ANNA M , BRYAN A FIAMENGO , KRISTINE E FRANK , FRIEDMAN MICHAEL , DAWN M GEORGE , ERIC R GOEDKEN , NATHAN S JOSEPHSOHN , BIQIN C LI , MICHAEL J MORYTKO , KENT D STEWART , VOSS JEFFREY W , GRIER AWALLACE , WANG LU , KEVIN R WOLLER
IPC分类号： C07D471/14 , A61K31/437 , A61K31/4985 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/02 , A61P5/06 , A61P5/10 , A61P5/14 , A61P5/38 , A61P7/00 , A61P7/02 , A61P7/04 , A61P7/06 , A61P7/08 , A61P7/10 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/16 , A61P13/02 , A61P13/12 , A61P15/08 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/22 , A61P25/28 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P33/02 , A61P33/14 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/00 , A61P39/04 , A61P43/00 , C07D487/14 , C07D519/00
CPC分类号： C07D487/14 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/14 , C07D498/14 , C07D513/14
摘要：【課題】1種以上の蛋白質キナーゼの活性を阻害して、免疫学的及び腫瘍学的状態を治療するために有用な化合物の提供。【解決手段】式(I)及び式(II)で表される化合物、これらの薬学的に許容される塩、プロドラッグ、生物活性代謝産物、立体異性体および異性体。(TはN又は置換炭素;UはN又は置換炭素等;XはN又は置換炭素等、YはN又はCの組み合わせ;R1〜R3、及びR5は、各々独立してH又は置換基)【選択図】なし
摘要翻译：待解决的问题：提供通过抑制一种或多种蛋白激酶的活性来治疗免疫学和肿瘤学病症的化合物。解决方案：本发明提供式（I）和式（II）的化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中T是N或取代的碳; U是N或取代的碳等; X是N或取代的碳等，Y是N或C的组合; R-R，和Rare独立地为H或取代基。

7. 发明专利

AU2020103475A4 Artificial Rainfall Device 未知
公开(公告)号：AU2020103475A4
公开(公告)日：2021-01-28
申请号：AU2020103475
申请日：2020-11-16
申请人： WANG LU
发明人： XIE XUHONG , LI CHANGBIN , WANG LU , WEI JIANMEI , WU LEI , LYU JIANAN , ZHANG YUAN
IPC分类号： A01G15/00
摘要： Abstract The artificial rainfall device comprises a sleeve (1), a water tank (2), a coiled plastic pipe (3) and a Tipping-bucket-type self-metering rain gauge (4), wherein a telescopic support rod (5) is movably connected inside the sleeve (1) A magnetic pump (7) is fixedly connected to one side of the bottom of the inner wall of the water tank (2), the water inlet of the magnetic pump (7) is communicated with a water pumping pipe (8), and the water outlet of the magnetic pump (7) is communicated with a water inlet pipe (9) which is far away from the magnetic pump (7) One end of the water inlet pipe (9) extending to the top of the water tank (2) is communicated with one end of the coiled plastic pipe (3) through a water inlet pipe interface (10), a water inlet valve (11) is fixedly connected inside the water inlet pipe (9), a precision flowmeter (12) is fixedly connected to one side of the surface top of the water inlet pipe (9), and a conical small hole is formed at the bottom of the surface of the coiled plastic pipe (3). 1525 14 6 5 13 3 1011 12 9 22 18 19 4 1 16 24 23 2 Figure 1 /Co/ - 10 Figure 2

8. 发明专利

CA3131777A1 DESIGN, MANUFACTURE, AND USE OF PERSONALIZED CANCER VACCINES 未知
公开(公告)号：CA3131777A1
公开(公告)日：2020-09-10
申请号：CA3131777
申请日：2020-02-28
申请人： FLOW PHARMA INC , RUBSAMEN REID M , HERST CHARLES V , WANG LU , BURKHOLZ SCOTT R , CARBACK RICHARD T , CIOTIOS SERBAN I
发明人： RUBSAMEN REID M , HERST CHARLES V , WANG LU , BURKHOLZ SCOTT R , CARBACK RICHARD T , CIOTIOS SERBAN I
IPC分类号： C12Q1/68 , A61K39/00 , A61P35/00 , A61P37/04 , C07K14/705 , C07K16/28 , C12Q1/6881 , G01N33/569 , G06N3/12 , G16B20/00 , G16B40/00
摘要： Personalized cancer vaccines are created by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Such a particle is created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

9. 发明专利

AU2020232971A1 Design, manufacture, and use of personalized cancer vaccines 未知
公开(公告)号：AU2020232971A1
公开(公告)日：2021-09-23
申请号：AU2020232971
申请日：2020-02-28
申请人： BURKHOLZ SCOTT R , CARBACK RICHARD T , CIOTIOS SERBAN I , FLOW PHARMA INC , HERST CHARLES V , RUBSAMEN REID M , WANG LU
发明人： RUBSAMEN REID M , HERST CHARLES V , WANG LU , BURKHOLZ SCOTT R , CARBACK RICHARD T , CIOTIOS SERBAN I
IPC分类号： A61K39/395 , C07K14/705 , C07K16/28 , C12Q1/68 , C12Q1/6881 , G01N33/569 , G06N3/12
摘要： Personalized cancer vaccines are created by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Such a particle is created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

10. 发明申请

WO2012129576A3 SYSTEM AND METHOD FOR BIPHASIC TRANSDERMAL IONTOPHREOTIC DELIVERY OF THERAPEUTIC AGENTS 审中-公开
标题翻译：用于治疗药物的双向超声心动图输送的系统和方法
公开(公告)号：WO2012129576A3
公开(公告)日：2012-12-27
申请号：PCT/US2012030633
申请日：2012-03-26
申请人： INCUBE LABS LLC , IMRAN MIR , HASHIM MIR , MCLAUGHLIN GLEN , ARASTU HUMA , VAIDYANATHAN REKHA , HARRIS JOEL , KORUPOLU RADHIKA , MANGOGNA ANDREW , ONG CHANG , PATEL SANJAY , WANG LU , WILLIAMS TIMOTHY
发明人： IMRAN MIR , HASHIM MIR , MCLAUGHLIN GLEN , ARASTU HUMA , VAIDYANATHAN REKHA , HARRIS JOEL , KORUPOLU RADHIKA , MANGOGNA ANDREW , ONG CHANG , PATEL SANJAY , WANG LU , WILLIAMS TIMOTHY
IPC分类号： A61N1/30 , A61K9/70 , A61N1/04 , A61N1/36
CPC分类号： A61N1/325 , A61K9/0009 , A61K9/0014 , A61K31/4178 , A61K31/4468 , A61K31/454 , A61K31/5415 , A61N1/0436 , A61N1/044 , A61N1/0448 , A61N1/30 , A61N1/303
摘要： Various embodiments provide methods and systems for the biphasic iontophoretic transdermal delivery of therapeutic agents. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient. Embodiments may be used for delivery of agents which cause adverse effects from unwanted passive diffusion.
摘要翻译：各种实施方案提供了用于治疗剂的双相离子电渗透皮递送的方法和系统。用于这种传送的方法的实施例包括将至少一个电极组件定位成与患者的皮肤电连通。组合物包括包含被动地扩散入皮肤的治疗剂的溶液。使用具有例如极性和大小的特性的第一电流，在第一时段期间，将剂量的药剂从组合物输送到皮肤中，以将药剂排斥出组合体。在第二时段期间，使用具有吸引剂的特性的第二电流将试剂保持在组合中，使得药剂递送到皮肤中最小化。可以根据患者的输入要求递送剂量。实施方案可以用于递送由不希望的被动扩散引起不利影响的试剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式